So, when we speak about metastatic CRPC, first, the most important change in the landscape is the definition of the disease itself. Previously, metastatic CRPC were patients progressing on androgen deprivation therapy alone. Now, if it hasn’t yet fully changed, it will soon. We are speaking about patients who have received ADT and an AR pathway inhibitor so that’s important so when we speak about metastatic CRPC we always have to speak about the historical one progressing on ADT alone and the intensified one progressing on a doublet...
So, when we speak about metastatic CRPC, first, the most important change in the landscape is the definition of the disease itself. Previously, metastatic CRPC were patients progressing on androgen deprivation therapy alone. Now, if it hasn’t yet fully changed, it will soon. We are speaking about patients who have received ADT and an AR pathway inhibitor so that’s important so when we speak about metastatic CRPC we always have to speak about the historical one progressing on ADT alone and the intensified one progressing on a doublet. The most important change is that clearly we’re not satisfied with ADT and an AR pathway inhibitor. We need to add something and that something is clearly in three directions: PARP inhibitor for those harboring BRCA1, 2 and maybe other mutations. Patients will have a high expression of PSMA for which we’re going to have a radioligand and those who have bone metastases for which we’re going to have radium. And finally, still, when do we feed in with docetaxel.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
